Federal officials are drafting an executive order that would place grants under review by an outside panel, the latest effort to redirect billions of dollars in research spending.

Xocova (ensitrelvir) is the first FDA-approved oral COVID post-exposure pill, cutting risk by 67% in the SCORPIO-PEP Phase 3 trial. What high-risk patients need to know.